• STAAR Surgical Q1 2026 earnings call featured Interim Co-CEO, President and COO Warren Foust, Interim Co-CEO and CFO Deborah J. Andrews, IR Director Connie Johnson.
• Net sales USD 93.5 million, up 119.6% y/y, driven by China net sales of USD 47.4 million on EVO+ launch and continued EVO demand; US posted first quarter above USD 6 million, up 22% y/y.
• Adjusted EBITDA swung to USD 24.4 million from loss of USD 26.3 million; gross margin rose to 73.6% from 65.8%, helped by lower period costs tied to Switzerland manufacturing ramp and lower inventory provisions.
• Management declined to endorse Street revenue view of USD 311 million-USD 312 million, citing macro and geopolitical uncertainty; Andrews said Q2 is tracking like a normal second quarter seasonally, with Q3 still uncertain.
• China channel inventory ended quarter at or below start-of-year levels, within targeted six-month range; early EVO+ demand exceeded plan, with full supply from Nidau facility expected by end of Q2, while Eyebright competition described as a “non-issue” so far.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STAAR Surgical Company published the original content used to generate this news brief on May 14, 2026, and is solely responsible for the information contained therein.